Published in AIDS Weekly, February 21st, 2005
Earlier this month, Ranbaxy had announced that it had begun filing data for its range of ARVs with the U.S. Food and Drug Administration (FDA) under it's expedited review process for the U.S. President's Emergency Program For Aids Relief (PEPFAR).
Speaking on the development, Dr. Brian W. Tempest, CEO and MD, Ranbaxy, said, "Ranbaxy fully supports WHO's prequalification project and we are working speedily to provide adequate fresh data to the WHO, on our generic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.